☆ 4.6 Meeting Abstract

Phase 1/2 Trial of the Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer (NSCLC)

JOURNAL OF THORACIC ONCOLOGY (2017)

Journal

JOURNAL OF THORACIC ONCOLOGY

Volume 12, Issue 1, Pages S1072-S1073

Publisher

ELSEVIER SCIENCE INC

DOI: 10.1016/j.jtho.2016.11.1500

Keywords

EGFR; HER2; AP32788; NSCLC

Categories

Oncology Respiratory System

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

No Data Available

No Data Available

No Data Available

© Peeref 2019-2024. All rights reserved.